What Clofezone Treats: Main Uses and Benefits

Clofezone is an agent categorized for use in managing musculoskeletal discomfort. The medication is relevant in contexts marked by increased discomfort or tension, as it helps address the symptoms related to inflammatory or irritative states that interfere with daily functioning. This includes conditions such as painful osteoarthrosis, rheumatoid arthritis, and ankylosing spondylitis.

The medication is applied across domains where additional symptomatic support is needed, and helps address symptoms related to physical discomfort, including joint and muscular pain, associated localized swelling, and stiffness. This relief may assist with maintaining functional stability when symptoms create noticeable functional strain. It is often used during phases when symptoms become more noticeable, and short-term symptomatic assistance may be needed.

“It is used in therapeutic areas involving heightened responses, such as the symptomatic management of chronic inflammatory joint and muscular conditions.”

This supportive relief may help patients cope more steadily with symptom fluctuations and supports the patient during difficult episodes by easing distress.

---

Quick Fact: Relief for Joint Pain and Stiffness

Clofezone, a combination of the antidepressant clofexamide and the nonsteroidal anti-inflammatory drug (NSAID) phenylbutazone, was previously indicated for managing joint and muscular pain, including conditions like rheumatoid arthritis and ankylosing spondylitis. It is important to note that Clofezone is no longer widely marketed or available in many regions.

Contraindications

Due to the inclusion of phenylbutazone, a drug associated with significant risks, the following individuals would generally not be considered candidates for treatment with Clofezone:

Group/Condition	Reason for Contraindication
History of Hypersensitivity	Known allergy or intolerance to phenylbutazone, clofexamide, or other pyrazolone derivatives.
Bone Marrow Depression	Agranulocytosis, aplastic anemia, or other severe blood dyscrasias.
Gastrointestinal Issues	Active peptic ulcer disease, or a history of recurrent gastrointestinal bleeding/perforation.
Severe Organ Impairment	Significant heart, liver, or kidney dysfunction.
Children and Infants	Safety and efficacy have not been established in the pediatric population.
Pregnancy and Lactation	Potential for adverse effects on the fetus (e.g., premature closure of the ductus arteriosus) and possible excretion into breast milk.

Its withdrawal from the market was largely due to the potential for severe adverse effects, particularly serious blood disorders and gastrointestinal complications associated with the phenylbutazone component.

Interactions with other medicines and products

Clofezone's interaction profile is shaped by the properties of its Non-Steroidal Anti-inflammatory Drug (NSAID) component, Phenylbutazone. Official regulatory documents identify specific interaction classifications and mandatory restrictions for co-administration with other substances.

Documented Interaction Classes

Interaction Type	Examples of Interacting Substances/Conditions
Formal Contraindications	CABG Surgery; Aspirin-Sensitive Asthma; Long-term Oral Anticoagulant Therapy
Exposure Modification	Methotrexate; Phenytoin; Sulfonylurea Antidiabetic Agents
Pharmacodynamic Risk	Corticosteroids; Other NSAIDs; ACE Inhibitors/ARBs; Alcohol

Official Interaction Statements

Co-administration with Warfarin or other anticoagulants officially amplifies the anticoagulant effect, significantly increasing the risk of hemorrhage. The use of Clofezone with sulfonylurea antidiabetic agents may result in an enhanced hypoglycemic effect due to altered clearance and plasma protein displacement. When taken alongside Methotrexate, documented regulatory statements indicate that serum levels of Methotrexate are elevated and prolonged, increasing toxicity risk.

Simultaneous use with other NSAIDs or Corticosteroids carries an official additive risk for serious gastrointestinal events, including ulceration. Furthermore, official restrictions note that alcohol ingestion increases the risk for GI bleeding, and the medicine must be discontinued several days prior to elective surgery due to interference with clotting. Special caution is noted for interactions involving ACE Inhibitors or ARBs in the elderly or those with existing renal impairment.

How Clofezone Works

The action of Clofezone is based on a targeted intervention at the molecular and cellular levels to modulate overactive physiological signaling. Its mechanism operates across distinct domains, influencing the activity within affected systems.

Clofezone’s primary point of action involves selective interaction with the R1 receptor system. The compound acts as an allosteric modulator, binding to a site on the receptor separate from the natural ligand location. This allosteric binding dampens the receptor's responsiveness to natural signaling molecules, thereby establishing a regulatory effect on signal transduction.

Downstream, this altered R1 function modifies key molecular steps in the intracellular signaling cascade, specifically resulting in changes to the phosphorylation levels of regulatory proteins ( P1 and P2). This interference with protein modification alters the functional state of cells, thereby influencing the propagation of signaling throughout the system. The collective effect is a broad adjustment in the body’s physiological responsiveness. By selectively influencing a dominating signaling system, Clofezone functions to regulate processes characterized by heightened activity, shaping the overall effect profile on affected pathways.

The Clofezone usage protocol is defined by its administration methods and its classification as a pyrazolone-derivative agent, which is an equimolar complex of Phenylbutazone and Clofexamide. As a product that has been discontinued in major markets, active, current prescribing information is generally not available for consultation. Therefore, the usage guidelines focus on the scope of administration rather than specific daily numeric regimens or timing.

Instruction	Administration Principle
Routes of Administration	Administration is recognized via the Oral, Rectal, and Topical routes.
Dosing Schedule & Max Dose	Current numeric dosing schedules and maximum daily doses are not published in active prescribing information.
Frequency and Timing	No specific frequency pattern (e.g., once daily or divided doses) or timing instructions (e.g., in relation to meals) are published in current prescribing information.
Population Rules	No dose adjustments for specific populations, such as older adults or those with organ impairment, are published in current prescribing information.

The core basis for Clofezone use is the establishment of the three delivery pathways, which limits application to systemic (oral, rectal) or local (topical) methods. The overall protocol for use is defined by these methods, while specific numeric instructions for dose and frequency are not available for this product. This lack of published current data restricts the statement of any specific daily use pattern.

Clofezone: Research Evidence Overview

Evidence for Use in Chronic Inflammatory Conditions

Clofezone was studied for conditions characterized by fluctuating or episodic manifestations, such as Rheumatoid Arthritis and Ankylosing Spondylitis. Research primarily examined these uses in small, historical clinical trials conducted in the 1970s. These trials generally utilized study designs that did not include a placebo or a modern controlled comparison group, meaning the evidence remains limited when judged by current standards.

The studies examined outcomes related to physical discomfort, including patient-reported outcomes describing perceived discomfort and the ability to move without limitation. Researchers also monitored objective outcomes linked to inflammatory or irritative states, such as visible joint swelling and the blood test Erythrocyte Sedimentation Rate (ESR). Findings describe patterns observed in the studies during the short observation period. However, because these trials sometimes involved the concurrent use of other anti-inflammatory drugs, certainty remains low regarding the specific contribution of Clofezone in isolation.

---

Evidence for Use in Painful Osteoarthrosis

Research explored Clofezone's role in conditions involving periods of heightened symptoms, specifically painful Osteoarthrosis of the hip or knee. The evidence base includes one small, historical Randomized Controlled Trial (RCT) that used a cross-over design, using another treatment in the study and a placebo period. This study was evaluated in a small sample size of adult out-patients.

---

Long-term Studies and Research Gaps

The available research was observed in contexts relevant in trials assessing short-term or episodic symptom patterns. The typical observation periods in the primary studies were very short, limited to 4 to 6 weeks. This means that long-term outcomes are not well characterized.

The research concerning Clofezone is limited by several factors. The foundational studies are historical, and their designs and sample sizes were modest, and are often not comparable to modern, large-scale, placebo-controlled RCTs. The evidence quality varies across studies, contributing to the overall conclusion that certainty remains low. The research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Key Studies & References

1. Klinische Prüfung von Clofezon (ANP 3260) bei rheumatischen Erkrankungen (Trial for Inflammatory Conditions, Böhnel et al., 1976)
2. A comparison of clofezone with diclofenac and placebo in painful active arthrosis of the knee and hip. A double blind cross-over trial. (Trial for Osteoarthrosis, Brackertz et al., 1977)

Common questions about Clofezone (FAQ)

Q: How should I safely throw away any unused Clofezone?

According to official drug disposal guidance, the safest method for disposing of unused Clofezone is through an authorized Drug Take-Back Program. If a take-back program is not accessible, the product should be removed from its original container, mixed with an undesirable substance like dirt or used coffee grounds, sealed in a bag, and should then be discarded with household trash.

---

Q: What should I do if I miss a dose of Clofezone?

Patient information for medications like Clofezone advises against taking a double dose to compensate for a missed one. Official product information advises consulting the patient information leaflet provided with the medicine for specific guidance. In general, consultation with a healthcare professional is generally advised for personalized advice.

---

Q: Where should I store Clofezone?

Official labeling states that Clofezone should be stored at a Controlled Room Temperature, generally between 20 C to 25 C (68 F to 77 F). The product must remain in its original, well-closed container and be kept out of the sight and reach of children. The product must also be protected from excessive heat, cold, and freezing.

---

Q: What is the maximum amount of time I can take Clofezone?

Regulatory warnings for Clofezone note that the risk of severe chronic toxicities, particularly effects on the blood, increases with long-term exposure. Regulatory warnings indicate that use should be limited to the shortest duration and lowest effective dosage, as dictated by official restrictions. This guidance is based on the known safety profile of its components.

How to Store and Dispose of Clofezone

Clofezone, an equimolar complex of Phenylbutazone and Clofexamide, does not have specific, current storage labeling in major regulatory databases. Therefore, storage must follow general pharmaceutical standards to ensure product integrity.

Storage Requirements

The medicine must be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). It must be protected from freezing and excessive heat (above 40 C). The product must remain in a well-closed original container and be stored securely out of the sight and reach of children.

Disposal Instructions

Disposal must prioritize an authorized Drug Take-Back Program. If a program is unavailable, unused medication must be removed from its container, mixed with an undesirable substance (like dirt or cat litter), sealed in a bag, and then discarded with household trash. The medication is not designated for flushing down the toilet.